GRDN Form 4 reports acquisition/exercise transactions

Burke Fred reported acquisition or exercise transactions in a Form 4 filing for GRDN.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Burke Fred reported acquisition or exercise transactions in a Form 4 filing for GRDN. The filing lists transactions totaling 75,000 shares. Following the reported transactions, holdings were 75,000 shares.

Insider Trade Summary

Grant/Award: 75,000 shares

Grant/Award 1 txn

Insider Burke Fred

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	75,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 75,000 contracts (Direct)

Footnotes (1)

F1. This option shall vest and become exercisable in full on February 11, 2029.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Guardian Pharmacy Services (GRDN) disclose?

Guardian Pharmacy Services disclosed that Fred Burke received a grant of 75,000 stock options. These options relate to Class A common stock and were awarded as equity-based compensation, expanding his derivative holdings linked to the company’s shares.

Who is Fred Burke in relation to Guardian Pharmacy Services (GRDN)?

Fred Burke is a director and serves as President and Chief Executive Officer of Guardian Pharmacy Services. His Form 4 filing reflects equity compensation he received in the form of stock options tied to the company’s Class A common stock.

What are the key terms of Fred Burke’s 75,000 Guardian Pharmacy (GRDN) stock options?

Fred Burke’s grant covers 75,000 stock options with an exercise price of $34.59 per share. The options are tied to Class A common stock and expire on February 11, 2036, providing a long-dated incentive aligned with company performance.

When do Fred Burke’s Guardian Pharmacy (GRDN) stock options vest?

The stock options granted to Fred Burke will vest and become fully exercisable on February 11, 2029. This single vesting date means he must remain in his role until then to benefit from the entire award under the stated terms.

How many Guardian Pharmacy (GRDN) derivative securities does Fred Burke own after this grant?

After this grant, Fred Burke beneficially owns 75,000 derivative securities in the form of stock options. All of these options are held directly and are linked to an equivalent number of underlying shares of Guardian Pharmacy’s Class A common stock.

What type of Form 4 transaction code was used in the Guardian Pharmacy (GRDN) filing?

The Form 4 uses transaction code “A,” indicating a grant, award, or other acquisition. This confirms that the 75,000 stock options received by Fred Burke represent a compensatory award rather than an open-market purchase or sale of existing securities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/13/2026 - 04:05 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Burke Fred

(Last)

(First)

(Middle)

300 GALLERIA PARKWAY SE, SUITE 800

(Street)

ATLANTA

30339

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Guardian Pharmacy Services, Inc. [ GRDN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$34.59	02/11/2026		A		75,000		⁽¹⁾	02/11/2036	Class A Common Stock	75,000	$0	75,000	D

Explanation of Responses:

1. This option shall vest and become exercisable in full on February 11, 2029.

Remarks:

President and Chief Executive Officer

	/s/ Douglas Towns, Attorney-in-Fact	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR